Editorials

Statins in acute kidney injury: friend or foe?

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f1531 (Published 19 March 2013) Cite this as: BMJ 2013;346:f1531
  1. Robert G Fassett, professor,
  2. Jeff S Coombes, professor
  1. 1School of Human Movement Studies, University of Queensland, Brisbane, QLD 4072, Australia
  1. rfassett{at}mac.com

Although protective in some circumstances, risk of developing AKI is increased, particularly with higher potency drugs

Statins have established benefits in the general population for primary and secondary prevention of cardiovascular disease. There has been a trend towards increasing the potency of statin treatment, either with larger doses—such as simvastatin or atorvastatin 40-80 mg—or with more potent forms, such as rosuvastatin. Potency is usually defined by the drug’s effect on reducing absolute low density lipoprotein-cholesterol, although the drugs’ well known pleiotropic effects are less easily quantified. Increased use of higher potency statins has partly stemmed from the outcomes of clinical trials such as the Treating to New Targets study, where high potency statins improved cardiovascular outcomes more than lower potency ones.

Because statins are now used so extensively, concerns have been expressed about their associated adverse events. In a linked paper (doi:10.1136/bmj.f880), using information from large patient databases, Dormuth and colleagues found that newly prescribed high potency statins were associated with increased risk of hospital admission for acute kidney …

Sign in

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe